Technical Analysis for AFMD - Affimed Therapeutics B.V.

Grade Last Price % Change Price Change
grade B 3.37 4.01% 0.13
AFMD closed up 4.01 percent on Monday, September 16, 2019, on 1.96 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical AFMD trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish 0.00%
Pocket Pivot Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Pocket Pivot Bullish Swing Setup 4.01%
Stochastic Reached Overbought Strength 4.01%
Upper Bollinger Band Walk Strength 4.01%

Older signals for AFMD ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Affimed Therapeutics B.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate includes AFM13, a natural killer cell bispecific antibody (TandAb) that has completed a Phase I clinical trial for the treatment of certain CD30-positive (CD30+) B- and T-cell malignancies, including hodgkin lymphoma. The company's product candidates also comprise AFM11, a T-cell TandAb for the treatment of certain CD19+ B-cell malignancies, including non-hodgkin lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Affimed Therapeutics B.V. has license agreements with Amphivena Therapeutics, Inc. to develop a product candidate for hematologic malignancies; and Xoma Ireland Limited to conduct research on immunoglobulins. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Medicine Biopharmaceutical Cancer Medical Specialties Solid Tumors Monoclonal Antibodies Lymphoma Glioblastoma Immunotherapies Chronic Lymphocytic Leukemia Seattle Genetics Hematologic Malignancies Head And Neck Cancer Non Hodgkin Lymphoma Tumors Of The Hematopoietic And Lymphoid Tissues Cd30 Hodgkin Lymphoma
Is AFMD a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.08
52 Week Low 2.52
Average Volume 556,870
200-Day Moving Average 3.3352
50-Day Moving Average 2.893
20-Day Moving Average 2.8745
10-Day Moving Average 2.98
Average True Range 0.1554
ADX 20.27
+DI 34.5261
-DI 9.6491
Chandelier Exit (Long, 3 ATRs ) 2.9638
Chandelier Exit (Short, 3 ATRs ) 3.0962
Upper Bollinger Band 3.2257
Lower Bollinger Band 2.5233
Percent B (%b) 1.21
BandWidth 24.435554
MACD Line 0.086
MACD Signal Line 0.0215
MACD Histogram 0.0645
Fundamentals Value
Market Cap 148.08 Million
Num Shares 43.9 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -3.39
Price-to-Sales 22.02
Price-to-Book 1.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.63
Resistance 3 (R3) 3.62 3.52 3.58
Resistance 2 (R2) 3.52 3.46 3.53 3.57
Resistance 1 (R1) 3.45 3.42 3.49 3.46 3.55
Pivot Point 3.35 3.35 3.37 3.36 3.35
Support 1 (S1) 3.28 3.29 3.32 3.29 3.19
Support 2 (S2) 3.18 3.25 3.19 3.17
Support 3 (S3) 3.11 3.18 3.16
Support 4 (S4) 3.12